Trial Profile
An Open Label, Dose-Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of TAK-981 in Adult Patients With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 15 Feb 2024
Price :
$35
*
At a glance
- Drugs Subasumstat (Primary)
- Indications Adenocarcinoma; Cervical cancer; Chronic lymphocytic leukaemia; Colorectal cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Takeda Oncology
- 09 Feb 2024 Status changed from active, no longer recruiting to discontinued due to enrollment difficulties.
- 04 Feb 2024 This trial has been completed in Poland according to European Clinical Trials Database record.
- 25 Jan 2024 This trial has been completed in Belgium (Global end date: 14 Dec 2023).